Prevention of CeCl3-induced hepatotoxicity by hypolipidemic compounds.
Pretreatment of rats with nafenopin, a hypolipidemic compound, prevents the lethality and hepatotoxicity induced by cerium chloride (CeCl3), a rare earth metal. The increase in hepatic triglycerides and the morphologic changes observed after 48 h of the CeCl3 injection (10 mg/kg) are completely abolished by nafenopin given for 4 days in doses of 250 mg/kg. However, an increase in the frequency of peroxisomes is noted in rats receiving nafenopin and CeCl3, attributable to the hypolipidemic drug pretreatment. In comparing the protective effect of nafenopin with that of CPIB (a structurally related compound) and lentysine (a structurally unrelated agent), it can be seen that nafenopin is about five times more active in decreasing liver triglycerides. The hepatic ultrastructure of rats pretreated with CPIB or lentysine is similar to that of CeCl3-treated controls.
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D002586:Cesium / Q000037:antagonists & inhibitors* / Q000633:toxicity; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology; D005260:Female; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008099:Liver / Q000378:metabolism / Q000473:pathology; D009255:Nafenopin / Q000494:pharmacology; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D014280:Triglycerides / Q000097:blood / Q000378:metabolism
D000960:Hypolipidemic Agents; D014280:Triglycerides; D009255:Nafenopin; D002586:Cesium; D002784:Cholesterol; D002994:Clofibrate; D000225:Adenine